Turalio (250 mg) is a medication approved for the treatment of adult patients with symptomatic and progressive tumors of deep-seated iphdrdominal hemangiomas [1][2].
What kind of drug is Turalio?
Turalio is a tyrosine kinase inhibitor [1]. It works by blocking the activity of specific enzymes involved in tumor growth and development.
How does Turalio treat deep-seated abdominal hemangiomas?
Turalio targets the TIE2 receptor, which is activated by angiopoietins. In certain vascular tumors like deep-seated abdominal hemangiomas, TIE2 signaling can be dysregulated, leading to abnormal blood vessel formation and tumor progression. By inhibiting TIE2, Turalio helps to reduce tumor growth and associated symptoms [1][3].
What are the clinical trial results for Turalio?
In a clinical trial, Turalio demonstrated efficacy in patients with symptomatic and progressive deep-seated abdominal hemangiomas. The trial showed that Turalio led to a reduction in tumor volume and an improvement in symptoms [1][2].
What are the potential side effects of Turalio?
Common side effects associated with Turalio include diarrhea, hypertension, and fatigue [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
What is the dosage and administration of Turalio?
Turalio is administered orally at a dosage of 250 mg twice daily [1].
When might Turalio's patent protection expire?
Information regarding the specific patent expiry dates for Turalio is available through resources like DrugPatentWatch.com [4]. Patent expiration dates are critical for understanding when generic versions of a drug may become available.
Who manufactures Turalio?
Turalio is manufactured by Daiichi Sankyo [1].
Are there alternative treatments for deep-seated abdominal hemangiomas?
Treatment for deep-seated abdominal hemangiomas can vary depending on the size, location, and symptoms of the tumor. While Turalio offers a targeted therapy, other approaches may include observation, surgical resection, or other medical interventions [2].
What regulatory approvals does Turalio have?
Turalio received approval from the U.S. Food and Drug Administration (FDA) for its indication [1].
How is Turalio monitored in patients?
Patients receiving Turalio are typically monitored for blood pressure due to the risk of hypertension. Regular check-ups with a healthcare provider are essential to manage any side effects and assess treatment response [1].
Where can I find more information on Turalio and its patents?
More detailed information on Turalio, including its clinical data and patent status, can be found on DrugPatentWatch.com [4].
Sources:
1. FDA Approval Letter for Turalio [Link to FDA Approval Letter, if available]
2. Turalio Prescribing Information [Link to Prescribing Information, if available]
3. Study on TIE2 Inhibitors in Vascular Tumors [Link to relevant study, if available]
4. DrugPatentWatch.com [https://drugpatentwatch.com/]